
Human mesenchymal stems exhibit green fluorescence after being ‘painted’ by the designer protein
In a world first, scientists have found a new way to direct stem cells to heart tissue. The findings, led by researchers at the University of Bristol and published in Chemical Science, could radically improve the treatment for cardiovascular disease, which causes more than a quarter of all deaths in the UK.
To date, trials using stem cells, which are taken and grown from the patient or donor and injected into the patient’s heart to regenerate damaged tissue, have produced promising results.
However, while these next generation cell therapies are on the horizon, significant challenges associated with the distribution of the stem cells have remained. High blood flow in the heart combined with various ’tissue sinks’, that circulating cells come into contact with, means the majority of the stem cells end up in the lungs and spleen.
Now, researchers from Bristol’s School of Cellular and Molecular Medicine have found a way to overcome this by modifying stem cells with a special protein so they ‘home’ to heart tissue.
Dr Adam Perriman, the study’s lead author, Associate Professor in Biomaterials, UKRI Future Leaders Fellow and founder of the cell therapy technology company CytoSeek, explained: “With regenerative cell therapies, where you are trying to treat someone after a heart attack, the cells rarely go to where you want them to go. Our aim is to use this technology to re-engineer the membrane of cells, so that when they’re injected, they’ll home to specific tissues of our choice.
“We know that some bacterial cells contain properties that enable them to detect and ‘home’ to diseased tissue. For example, the oral bacterial found in our mouths can occasionally cause strep throat. If it enters the blood stream it can ‘home’ to damaged tissue in the heart causing infective endocarditis. Our aim was to replicate the homing ability of bacteria cells and apply it to stem cells.”
The team developed the technology by looking at how bacterial cells use a protein called an adhesin to ‘home’ to heart tissue. Using this theory, the researchers were able to produce an artificial cell membrane binding version of the adhesin that could be ‘painted’ on the outside of the stem cells. In an animal model, the team were able to demonstrate that this new cell modification technique worked by directing stem cells to the heart in a mouse.
Dr Perriman added: “Our findings demonstrate that the cardiac homing properties of infectious bacteria can be transferred to human stem cells. Significantly, we show in a mouse model that the designer adhesin protein spontaneously inserts into the plasma membrane of the stem cells with no cytotoxity, and then directs the modified cells to the heart after transplant. To our knowledge, this is the first time that the targeting properties of infectious bacteria have been transferred to mammalian cells.
“This new technique carries enormous potential for the seven million people currently living with heart disease in the UK.”
Learn more: Scientists hijack bacteria’s homing ability
The Latest on: Cardiovascular disease
via Google News
The Latest on: Cardiovascular disease
- Fatty liver disease symptoms: Red palms could be sign of ‘aggressive’ form of conditionon January 23, 2021 at 2:21 am
FATTY liver disease, also known as nonalcoholic fatty liver disease, can lead to serious health complications if left untreated. Red palms can be a sign of an "aggressive" form of the condition - ...
- New perspectives challenge the idea that saturated fats cause heart diseaseon January 22, 2021 at 8:34 am
In science, sometimes a new perspective can turn our interpretation of the data upside-down, and necessitate a paradigm shift.
- Biodegradable Stents Market: Rising Incidence of Cardiovascular Disease to Boost Demand for the Marketon January 22, 2021 at 6:35 am
The demand within the global biodegradable stents market is ascending at an exponential rate in recent times. Presence of an ever-evolving domain of ...
- Simple count of social determinants of health may help predict patients' fatal heart disease riskson January 21, 2021 at 9:05 pm
Doctors may be able to predict their patients' risks of fatal coronary heart disease more accurately by taking into account the number of adverse social factors affecting them, according to a new ...
- Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseaseson January 21, 2021 at 1:30 pm
Amarin Corporation plc today announced that the Chinese Society of Cardiology has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as ...
- Scientists may have found a way to 'de-age the brain': Switching off certain immune cells could delay the onset of Alzheimer's disease, cancer and heart disease, study findson January 20, 2021 at 8:37 am
In the study, researchers from Stanford Medicine switched off myeloid cells in old mice, as well as myeloid cells in culture from people older than 65 and under 35.
- Fried Food Raises Risk for Heart Disease, Strokeon January 20, 2021 at 8:13 am
Eating fried food is tied to an increased risk of heart disease and stroke, a new study suggests. The risk rises with each additional 4-ounce serving per week, a research team in China found. For the ...
- Diabetes powerfully associated with premature coronary heart disease in womenon January 20, 2021 at 8:04 am
While deaths related to heart disease have declined among older people, studies suggest that death rates among younger patients have remained stagnant or increased slightly. To understand what factors ...
- Fried food a big factor in heart disease, strokeon January 19, 2021 at 10:05 pm
Eating fried food is tied to an increased risk of heart disease and stroke, a new study suggests. The risk rises with each additional 4-ounce serving per week, a research team in China found. For the ...
- Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Diseaseon January 19, 2021 at 10:02 pm
Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced the successful completion of a $94 million Series B financing, led by ...
via Bing News